Dr Matthew Galsky speaks to ecancer about the phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients. Initially he explains the rationale of the study. Dr Galsky then, explains the methodology and key results of this trial.
He concludes that transurethral resection of bladder tumour + gemcitabine, cisplatin, plus nivolumab achieves stringently defined cCR in a large subset of patients with MIBC.
1-year bladder intact survival is possible though the durability of responses, and role of genomic biomarkers in management algorithms, requires longer follow-up.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.